Costco is stepping into the weight-loss drug market by teaming up with Danish pharmaceutical giant Novo Nordisk to sell Ozempic and Wegovy at discounted prices across its US. pharmacies.
The new partnership aims to make the two popular medications more affordable and easier to access for consumers who already shop at Costco.
Both drugs are now priced at $499 for a one-month supply, significantly lower than their usual retail costs, which can reach $1,300 for Ozempic and $1,600 for Wegovy, according to GoodRx, CBS News reported.
Costco executive members and those who use a Costco Citibank Visa card can get an extra 2% discount, but customers will still need a valid prescription to purchase the medications.
Dave Moore, executive vice president of US operations at Novo Nordisk, said the partnership reflects the company's goal of helping more people access FDA-approved treatments safely.
"By partnering with one of the country's most trusted retailers, we are meeting people where they are and connecting them to real, FDA-approved medicines," Moore said.
Ozempic and Wegovy are both semaglutide-based injections that work by suppressing appetite, which helps with weight loss.
While Ozempic is mainly prescribed for adults with Type 2 diabetes, it has also been shown to reduce heart and kidney risks.
#News: We are excited to announce our collaboration with @Costco Pharmacy! Costco members who are self-paying patients can now access Wegovy® and Ozempic® at their convenient locations. This exemplifies our commitment to expanding patient access to FDA-approved medicines. pic.twitter.com/JZcmx5hJSF
— Novo Nordisk US (@novonordiskus) October 3, 2025
FDA Says Wegovy and Ozempic Shortages Over
Wegovy, unlike Ozempic, has full FDA approval for weight loss and is commonly prescribed to adults dealing with obesity or heart-related health issues.
Recently, the US Food and Drug Administration confirmed that the nationwide shortage of both drugs has finally been resolved.
This update may also slow the rising trend of cheaper, compounded versions being sold online or through medical spas, which the FDA has cautioned against due to safety and quality concerns.
Novo Nordisk's decision to bring its medications to Costco comes at a competitive time.
The company is facing increasing pressure from Eli Lilly, whose weight-loss treatments Zepbound and Mounjaro have been gaining traction.
As more Americans turn to GLP-1 medications for help managing weight and diabetes, the focus has shifted toward making these drugs more affordable and easier to get.
However, insurance coverage remains a big hurdle. A report from consulting firm Mercer found that less than half of large employer health plans cover GLP-1 drugs when used for weight loss because of their steep price tags.
According to USA Today, in 2024, only 44% of companies offered that benefit, even though demand for these medications continues to surge.
Join the Conversation